만성 폐고혈압 : 시장 인사이트, 역학 및 시장 예측(2036년)

Chronic Pulmonary Hypertension (CPH) Insights and Trends

• Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) represent two major subtypes of pulmonary hypertension, with CTEPH categorized under Group 4 pulmonary hypertension.
• Chronic Pulmonary Hypertension (CPH), particularly chronic thromboembolic pulmonary hypertension (CTEPH), is a progressive and life-threatening condition characterized by persistent elevation of pulmonary arterial pressure due to unresolved pulmonary emboli and vascular remodeling. The disease leads to increased pulmonary vascular resistance, right heart failure, and significant morbidity and mortality if left untreated.
• A significant proportion of CPH burden is associated with comorbid conditions such as chronic kidney disease, cancer, chronic heart failure, inflammatory bowel disease, celiac disease, and women's health-related factors, with chronic kidney disease contributing the largest share, highlighting the need for integrated disease management, early screening, and targeted treatment approaches to reduce complications and improve patient outcomes.
• Pulmonary endarterectomy (PEA) remains the gold-standard and potentially curative treatment for operable CTEPH patients
• For patients who are not eligible for surgery, treatment options include pulmonary vasodilator-based medical therapy and balloon pulmonary angioplasty (BPA) to improve pulmonary blood flow and reduce disease burden
• In the CPH market across the 7MM Riociguat (ADEMPAS), accounts for the largest share among treatment options, driven by its widespread use in moderate-to-severe patients requiring rapid and effective iron repletion.
• Currently, Riociguat (ADEMPAS) and BPA ought to be viewed as complementary rather than competing therapies for inoperable CTEPH.
• Whereas the emerging CPH pipeline remains relatively limited and have the potential to create a significant positive shift in the CPH Market Size.
• Clinical trials are needed to evaluate new combination therapies and the effectiveness of multidisciplinary care models, ensuring optimized and personalized treatment strategies for all patients.

DelveInsight's 'Chronic Pulmonary Hypertension (CPH) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the CPH, historical and forecasted epidemiology, as well as the CPH market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The CPH market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, CPH patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in CPH and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Chronic Pulmonary Hypertension (CPH) Market

Rising CPH Prevalence

Rising Opportunities in Targeted Iron Therapies

Emerging advances in pulmonary vascular biology and targeted drug development highlight growing opportunities for therapies that address underlying disease mechanisms, improve hemodynamics, and potentially modify disease progression beyond symptomatic relief.

Chronic Pulmonary Hypertension (CPH) Understanding and Treatment Algorithm

Chronic Pulmonary Hypertension (CPH) Overview and Diagnosis

CPH is a progressive cardiovascular condition characterized by persistently elevated pressure in the pulmonary arteries, leading to increased strain on the right side of the heart and impaired blood flow through the lungs. It can range from mild to severe, with symptoms such as shortness of breath, fatigue, and chest discomfort, and syncope, particularly in advanced stages. CPH is primarily caused by underlying conditions such as chronic lung diseases, left heart disorders, recurrent pulmonary embolism, or idiopathic vascular remodeling. Diagnosis is based on imaging, echocardiography, and confirmatory right heart catheterization.

Chronic Pulmonary Hypertension (CPH) Diagnosis

Chronic Pulmonary Hypertension (CPH) is diagnosed through clinical evaluation and imaging, often suspected in patients with unexplained breathlessness and fatigue. Echocardiography is the primary screening tool to estimate pulmonary artery pressure and assess heart function. Confirmation is done by right heart catheterization, which directly measures pulmonary pressures. Additional tests such as ECG, chest X-ray, and CT or V/Q scan help identify underlying causes.

Chronic Pulmonary Hypertension (CPH) Treatment

The primary goals of CPH treatment are to reduce pulmonary arterial pressure, improve exercise capacity and quality of life, slow disease progression, and prevent right heart failure. Management is largely pharmacologic and follows a step-wise, combination-based approach. First-line therapies include endothelin receptor antagonists along with phosphodiesterase-5 inhibitors to promote vasodilation. In patients with more advanced disease, prostacyclin pathway agents are used to enhance pulmonary vascular relaxation and inhibit proliferation. Soluble guanylate cyclase stimulators such as Riociguat (ADEMPAS) may also be considered, particularly in specific subtypes. Supportive measures, including oxygen therapy, diuretics, anticoagulation in selected patients, and lifestyle modifications, play a critical role in comprehensive disease management and long-term outcomes.

Chronic Pulmonary Hypertension (CPH) Unmet Needs

The section "unmet needs of CPH" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Delayed diagnosis due to non-specific symptoms

2. Limited awareness and inadequate screening

3. Poor understanding of disease progression and heterogeneity

4. High cost and limited access to advanced diagnostics, and others.....

Comprehensive unmet needs insights in Chronic Pulmonary Hypertension (CPH) and their strategic implications are provided in the full report.

Chronic Pulmonary Hypertension (CPH) Epidemiology

Key Findings from Chronic Pulmonary Hypertension (CPH) Epidemiological Analysis and Forecast

• The CPH prevalent cases were segmented based on age in four age-groups <45 years, 45-54 years, 55-64 years, 65 years and above. Our estimate suggests that in the US highest number of cases were in the age group 65 years and above and the least in <45 years in 2025.
• Assessments as per DelveInsight's analysts show that the majority of cases of CPH are occupied by females in comparison to males.

Chronic Pulmonary Hypertension (CPH) Drug Chapters & Competitive Analysis

The CPH drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the CPH treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the CPH therapeutics market.

Approved Therapies for Chronic Pulmonary Hypertension (CPH)

Riociguat (ADEMPAS): Bayer/Merck

Riociguat is an oral sGC stimulator that enhances nitric oxide signaling, leading to vasodilation and improved pulmonary hemodynamics. Approved by the US FDA in 2013 for the treatment of adults with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4). It improves exercise capacity and delays disease progression, supporting its clinical utility.

Chronic Pulmonary Hypertension (CPH) Pipeline Analysis

In CPH, companies worldwide have demonstrated limited engagement in developing truly disease-modifying and targeted therapies, with most available options focused on symptom management. As a result, the pipeline remains constrained, and the treatment landscape lacks a clearly defined market leader with curative potential.

Chronic Pulmonary Hypertension (CPH) Key Players, Market Leaders and Emerging Companies

• Bayer
• Merck, and others

Chronic Pulmonary Hypertension (CPH) Drug Updates

In May 2014, Bayer and Merck formed a global co-development and co-commercialization partnership for sGC modulators, including riociguat. Under this agreement, Bayer markets ADEMPAS in the US, while Merck handles commercialization in the rest of the world.

Chronic Pulmonary Hypertension (CPH) Market Outlook

The CPH market is gradually evolving, shifting from conventional vasodilator-based therapies toward more targeted and mechanism-driven approaches aimed at addressing vascular remodeling, inflammation, and right heart dysfunction. The increasing focus on combination regimens and novel pathways, including prostacyclin analogs, endothelin receptor antagonists, and soluble guanylate cyclase stimulators, reflects ongoing efforts to improve clinical outcomes, functional capacity, and long-term survival. These advancements highlight a transition toward more personalized and optimized treatment strategies, enhancing both physician confidence and patient management.

With continued research into disease-modifying therapies targeting underlying pathophysiology, the CPH treatment landscape is expected to expand in line with other chronic cardiovascular disorders. The United States remains a leading market, supported by higher diagnosis rates, advanced healthcare infrastructure, strong awareness, and early adoption of innovative therapies compared to Europe and Japan.

Overall, increasing disease awareness, improvements in diagnostic capabilities, growing use of combination therapies, and the development of novel targeted agents are expected to drive steady growth in the 7MM CPH market over the forecast period, creating meaningful opportunities for both existing therapies and emerging pipeline candidates.

• The CPH treatment landscape is evolving as management shifts from conventional monotherapy toward combination regimens, with advanced targeted agents such as Adempas (riociguat), driving adoption due to improved clinical outcomes and broader applicability across patient groups.
• Regional market dynamics indicate that the United States leads in revenue, while Japan and key European Union markets show steady growth, supported by increasing diagnosis rates, improved access to advanced therapies, and rising use of combination treatment strategies.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chronic Pulmonary Hypertension (CPH) (2022-2036 Forecast)

The CPH market comprises vasodilator therapies, targeted pathway-specific agents, combination regimens, and supportive/non-drug interventions, each addressing distinct mechanisms such as pulmonary vascular resistance, endothelial dysfunction, and right heart strain.

• Conventional vasodilator therapies: Agents such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs remain the cornerstone of treatment, improving hemodynamics and symptoms but with limited impact on disease reversal.
• Targeted pathway therapies: Newer agents focusing on pathways like nitric oxide, endothelin, and prostacyclin signaling aim to optimize disease control, reflecting a shift toward mechanism-based treatment strategies.
• Combination therapies: Use of dual or triple drug regimens is increasingly adopted to enhance clinical outcomes, though challenges remain in optimal sequencing, tolerability, and cost.
• Supportive and non-drug interventions: Oxygen therapy, anticoagulation, lifestyle modifications, and surgical options such as pulmonary endarterectomy or lung transplantation play a critical role in comprehensive disease management.

Overall, combination and targeted therapies define the evolving treatment landscape in CPH, with current approaches focused on symptom control and disease stabilization, while the need for curative and disease-modifying options continues to drive future innovation.

Chronic Pulmonary Hypertension (CPH) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the CPH market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Established therapies demonstrate moderate to high uptake, while newer agent such as Adempas (riociguat) is anticipated to show gradual growth, supported by improved efficacy, combination strategies, and convenient administration routes. Their adoption is driven by the limitations of existing treatments, including incomplete disease control and complex dosing regimens. In comparison, next-generation therapies targeting novel pathways are expected to witness steady uptake as clinical evidence expands and treatment guidelines evolve across diverse patient populations.

Market Access and Reimbursement of CPH

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Further details are provided in the final report....

Chronic Pulmonary Hypertension (CPH) Therapies Price Scenario & Trends

Pricing and analogue assessment of CPH therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Chronic Pulmonary Hypertension (CPH)

To keep up with CPH market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the CPH emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in CPH, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the Harvard Medical School, University of Nottingham, and Japanese Red Cross Central Blood Institute, etc. were contacted. Their opinion helps understand and validate current and emerging CPH therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in CPH.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of CPH, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of CPH, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the CPH market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM CPH market.

Report Insights

• Chronic Pulmonary Hypertension (CPH) Patient Population Forecast
• Chronic Pulmonary Hypertension (CPH) Therapeutics Market Size
• Chronic Pulmonary Hypertension (CPH) Pipeline Analysis
• Chronic Pulmonary Hypertension (CPH) Market Size and Trends
• Chronic Pulmonary Hypertension (CPH) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Chronic Pulmonary Hypertension (CPH) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chronic Pulmonary Hypertension (CPH) Treatment Addressable Market (TAM)
• Chronic Pulmonary Hypertension (CPH) Competitive Landscape
• Chronic Pulmonary Hypertension (CPH) Major Companies Insights
• Chronic Pulmonary Hypertension (CPH) Price Trends and Analogue Assessment
• Chronic Pulmonary Hypertension (CPH) Therapies Drug Adoption/Uptake
• Chronic Pulmonary Hypertension (CPH) Therapies Peak Patient Share analysis

Report Assessment

• Chronic Pulmonary Hypertension (CPH) Current Treatment Practices
• Chronic Pulmonary Hypertension (CPH) Unmet Needs
• Chronic Pulmonary Hypertension (CPH) Clinical Development Analysis
• Chronic Pulmonary Hypertension (CPH) Emerging Drugs Product Profiles
• Chronic Pulmonary Hypertension (CPH) Market Attractiveness
• Chronic Pulmonary Hypertension (CPH) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Chronic Pulmonary Hypertension (CPH) market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Chronic Pulmonary Hypertension (CPH)?
• What are the disease risks, burdens, and unmet needs of Chronic Pulmonary Hypertension (CPH)? What will be the growth opportunities across the 7MM concerning the patient population with Chronic Pulmonary Hypertension (CPH)?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Chronic Pulmonary Hypertension (CPH)? What are the current guidelines for treating Chronic Pulmonary Hypertension (CPH) in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Chronic Pulmonary Hypertension (CPH) market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Chronic Pulmonary Hypertension (CPH) Market Overview at a Glance

• 6.1. Market Share (%) Distribution of CPH By Therapies in the 7MM, in 2025
• 6.2. Market Share (%) Distribution of CPH By Therapies in the 7MM, in 2036

7. Disease Background and Overview of Chronic Pulmonary Hypertension (CPH)

• 7.1. Introduction
• 7.2. Classification
• 7.3. Signs and Symptoms of CPH
• 7.4. Causes of CPH
• 7.5. Risk factors of CPH
• 7.6. Pathophysiology of CPH
• 7.7. Diagnosis of CPH
  • 7.7.1. Differential Diagnosis
  • 7.7.2. Diagnostic Algorithm of CPH
  • 7.7.3. Guidelines for the Diagnosis of CPH

8. Treatment

• 8.1. Algorithm for the Treatment of CPH
• 8.2. Guidelines for the Treatment of CPH

9. Epidemiology and Patient Population of Chronic Pulmonary Hypertension (CPH)

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Diagnosed Prevalent Cases of CPH in the 7MM
• 9.4. The United States
  • 9.4.1. Total Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in the US
  • 9.4.2. Group-specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in the US
  • 9.4.3. Gender-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in the US
  • 9.4.4. Age-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in the US
  • 9.4.5. Total Treated Cases of Chronic Pulmonary Hypertension (CPH) in the US
• 9.5. EU4 and the UK
  • 9.5.1. Total Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in EU4 and the UK
  • 9.5.2. Group-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in EU4 and the UK
  • 9.5.3. Gender-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in EU4 and the UK
  • 9.5.4. Age-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in EU4 and the UK
  • 9.5.5. Total Treated Cases of Chronic Pulmonary Hypertension (CPH) in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in Japan
  • 9.6.2. Group-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in Japan
  • 9.6.3. Gender-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in Japan
  • 9.6.4. Age-Specific Prevalent Cases of Chronic Pulmonary Hypertension (CPH) in Japan
  • 9.6.6. Total treated Cases of Chronic Pulmonary Hypertension (CPH) in Japan

10. Patient Journey of Chronic Pulmonary Hypertension (CPH)

11. Marketed Therapies

• 11.1. Marketed Competitive Landscape of Chronic Pulmonary Hypertension (CPH)
• 11.2. ADEMPAS (Riociguat): Bayer/Merck
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views

12. Chronic Pulmonary Hypertension (CPH): 7MM Analysis

• 12.1. Key Findings
• 12.2. Market Outlook of Chronic Pulmonary Hypertension (CPH)
• 12.3. Key Market Forecast Assumptions
  • 12.3.1. Cost Assumptions
  • 12.3.2. Pricing Trends
  • 12.3.3. Analogue Assessment
  • 12.3.4. Launch Year and Therapy Uptakes
• 12.4. Conjoint Analysis of Chronic Pulmonary Hypertension (CPH)
• 12.5. Total Market Size of CPH in the 7MM
• 12.6. Total Market Size of CPH by Therapies in the 7MM
• 12.7. The United States
  • 12.7.1. Total Market Size of CPH in the United States
  • 12.7.2. Total Market Size of CPH by Therapies in the United States
• 12.8. EU4 and the UK
  • 12.8.1. Total Market Size of CPH in EU4 and the UK
  • 12.8.2. Total Market Size of CPH by Therapies in EU4 and the UK
• 12.9. Japan
  • 12.9.1. Total Market Size of CPH in Japan
  • 12.9.2. Total Market Size of CPH by Therapies in Japan

13. Unmet Needs of Chronic Pulmonary Hypertension (CPH)

14. SWOT Analysis of Chronic Pulmonary Hypertension (CPH)

15. KOL Views of Chronic Pulmonary Hypertension (CPH)

16. Market Access and Reimbursement of Chronic Pulmonary Hypertension (CPH)

• 16.1. The United States
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of CPH Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight